about
Preclinical therapy of disseminated HER-2⁺ ovarian and breast carcinomas with a HER-2-retargeted oncolytic herpesvirus.Genetic prevention of lymphoma in p53 knockout mice allows the early development of p53-related sarcomasInterleukin-15 is required for immunosurveillance and immunoprevention of HER2/neu-driven mammary carcinogenesis.Systemic delivery of HER2-retargeted oncolytic-HSV by mesenchymal stromal cells protects from lung and brain metastases.Tumor suppressor genes promote rhabdomyosarcoma progression in p53 heterozygous, HER-2/neu transgenic mice.A module of inflammatory cytokines defines resistance of colorectal cancer to EGFR inhibitors.Vaccines against human HER2 prevent mammary carcinoma in mice transgenic for human HER2.Combining three antibodies nullifies feedback-mediated resistance to erlotinib in lung cancer.
P50
Q34574879-EE211AA1-AD8E-4F97-A30F-20EDCF22E1C1Q35067979-27467AEB-3255-47E0-A1CD-3E48AF0B23C1Q35710332-66DF2F4B-8E0D-4EEA-A153-3B6909B2BD96Q36544212-B83DA267-DAE6-4AAD-9514-228FD94CD858Q37649642-3EF0CCBB-29F8-42C8-8C80-3C3B9217E59EQ37687796-85E783A0-4692-4DE4-A283-6D15B3FF12F4Q37691212-2F105C36-506D-4FE9-8E51-13E8E5CCFF90Q38868047-12FEF994-40E5-449C-89CA-71E9515B4830
P50
description
investigador
@es
researcher
@en
name
Massimiliano Dall'ora
@en
type
label
Massimiliano Dall'ora
@en
prefLabel
Massimiliano Dall'ora
@en
P31
P496
0000-0002-7790-9859